UPDATED July 28, 2023 // Editor's note: This article has been updated to clarify the comments and viewpoints of Dr Amy Paller.
ASHEVILLE, N.C. — Treating atopic dermatitis (AD) in most children — and working with parents — might be less dependent on the next, even better therapy than considering facets of poor response and dissatisfaction with treatment, according to a three-member expert panel mulling over strategies at the annual meeting of the Society for Pediatric Dermatology.
In introductory remarks, the three panelists briefly addressed different aspects for controlling AD, including drugs in the pipeline, the potential value of alternative therapies, and whom to blame when compliance is poor.
But panel discussion following these presentations provided an opportunity for audience engagement on practical strategies for improving AD control.

Dr Amy Paller
In her formal remarks prior to the panel discussion, Amy S. Paller, MD, professor of dermatology and pediatrics, and chair of dermatology, Northwestern University, and a pediatric dermatologist at the Lurie Children's Hospital of Chicago, described emerging AD treatments. This included an update on the status of the interleukin-13 (IL-13) inhibitors tralokinumab (Adbry), which was approved by the FDA for treating AD in adults in December 2021, and lebrikizumabwhich is thought likely to be soon approved in the United States on the basis of two recently published